Related Experiment Video
Updated: Dec 6, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Natural history of nonbacterial thrombotic endocarditis treated with warfarin
Andrew P Slivka1, Julie E Agriesti1, David A Orsinelli2
1Department of Neurology, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.
Insights
Warfarin effectively treats nonbacterial thrombotic endocarditis (NBTE) in patients with stroke or transient ischemic attack (TIA). Most valvular vegetations resolve, and switching to aspirin is safe, with a low risk of recurrent stroke.
Area of Science:
- Cardiology
- Neurology
- Rheumatology
Background:
- Nonbacterial thrombotic endocarditis (NBTE) is a rare condition associated with stroke.
- Management of NBTE in patients experiencing transient ischemic attack (TIA) or stroke remains challenging.
- Optimal anticoagulation strategies for NBTE require further investigation.
Purpose of the Study:
- To describe the natural history of NBTE in patients with TIA or stroke.
- To evaluate the efficacy and safety of warfarin treatment followed by aspirin.
- To provide treatment recommendations for this patient population.
Main Methods:
- Retrospective analysis of 29 patients with NBTE, TIA, or stroke treated with warfarin.
- Warfarin was administered until vegetation resolution or for two years, then switched to aspirin.
- Clinical and echocardiographic follow-up was performed.
Main Results:
- Valvular vegetations resolved in 74% of affected valves after a median of 11 months.
- Recurrent strokes occurred in 17% of patients, with some linked to antiphospholipid antibodies or systemic lupus erythematosus.
- No recurrent vegetations were observed after switching from warfarin to aspirin.
Conclusions:
- Warfarin is effective in resolving NBTE and reducing stroke risk in affected patients.
- Switching to aspirin is generally safe after vegetation resolution or two years of warfarin.
- Prolonged warfarin may be considered for patients with persistent vegetations and associated autoimmune conditions.
Abstract:
We report on the natural history of a cohort of patients presenting with transient ischemic attack or stroke and nonbacterial thrombotic endocarditis treated with warfarin.Patients with valvular vegetations on echocardiography, stroke, or transient ischemic attack presenting to a single neurologist were included. All patients were treated with warfarin until the vegetation resolved or for two years, then were switched to aspirin and had at least one clinical and echocardiographic follow-up.Twenty-nine patients were included and followed for a median of 27 months. Average age was 42 years and 72% were female. Two patients had vegetations on two valves. Five patients (17%) had recurrent strokes, three had systemic lupus erythematosus and antiphospholipid antibodies, one had antiphospholipid antibodies alone and one had neither condition. Three of the five patients did not have resolution of the vegetation at the time of the event. The valvular vegetations resolved in 23 of the 31 affected valves (74%) after a median of 11 months (range 4.5-157.5). Eleven patients had at least one follow-up echocardiogram after resolution of the vegetation and none had recurrent vegetations after warfarin was stopped.This study should serve to provide general recommendations regarding treatment of patients with TIA/stroke with nonbacterial thrombotic endocarditis. Valvular vegetations resolve in most patients and the risk of recurrent stroke is low. Warfarin can safely be switched to aspirin in most patients when the vegetation resolves or after two years if it does not resolve. Prolonged warfarin may be warranted in patients with systemic lupus erythematosus, positive antiphospholipid antibodies, and a persistent vegetation.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Endocarditis III: Medical Management
Endocarditis I: Introduction
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Endocarditis II: Clinical Features of Infective Endocarditis
Anticoagulant Drugs: Low-Molecular-Weight Heparins

